My watch list  

Omega Pharma

Omega Pharma NV
HeadquartersNazareth, Belgium
Key peopleMarc Coucke (Chairman of the board), Jan Cassiman (CEO)
ProductsPrescription-free medicines and healthcare products, products and services for medical professionals
Revenue€1.017 billion (2006)

Omega Pharma is a Belgian Pharmaceutical company, founded in 1987 by Marc Coucke (b. 1965) and Yvan Vindevogel, both former Pharmacy students at the Ghent University.

The company is quoted at Euronext Brussels and makes part of the BEL20 index.


At the occasion of the annual shareholders meeting of June 6th 2006; Omega Pharma announced the name under which its Professional Health division will henceforward operate: Arseus. Simultaneously, the management team of Arseus was presented. The legal structure of the entities in this division has been largely prepared in the mean time, so that the project to make Arseus an autonomous company is on schedule. In the framework of this project, it is expected that Arseus, as an autonomous company, will become stock-listed by 2008.

Arseus covers the activities of Omega Pharma that are targeted towards professional users in the pharmaceutical and medical environment, like pharmacists, medical practitioners in various medical disciplines (dentists, ophthalmologists, …), opticians, nurses, professional staff in hospitals, caring homes and nursing homes. These activities have until now been organised according to the corresponding business units of Omega Pharma; i.e.: the activities of the Fagron Group (raw materials and equipment for the pharmacy), OmegaSoft [1] (IT solutions for the medical environment), Omega Dental (products and services for dental surgery and dental care), Omega Medical (products and services for hospitals, healthcare institutions, home care and nursing homes).

Arseus has approximately 1,300 employees, spread throughout Belgium, the Netherlands, France, Germany, Spain and Switzerland. Arseus plans to expand its activities towards all other European markets.

In 2005, the Professional Health Division, now Arseus, generated an annual turnover of EUR 284 million, which is 30% of the consolidated turnover of Omega Pharma.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Omega_Pharma". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE